664 related articles for article (PubMed ID: 31158077)
1. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
[TBL] [Abstract][Full Text] [Related]
2. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Biochemical Recurrence-Free Survival after Radical Prostatectomy Triggered by Grade Reclassification during Active Surveillance and in Men Newly Diagnosed with Similar Grade Disease.
Diniz CP; Landis P; Carter HB; Epstein JI; Mamawala M
J Urol; 2017 Sep; 198(3):608-613. PubMed ID: 28347771
[TBL] [Abstract][Full Text] [Related]
4. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.
Balakrishnan AS; Cowan JE; Cooperberg MR; Shinohara K; Nguyen HG; Carroll PR
J Urol; 2019 Sep; 202(3):506-510. PubMed ID: 30958738
[TBL] [Abstract][Full Text] [Related]
6. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.
Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213
[TBL] [Abstract][Full Text] [Related]
7. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
[TBL] [Abstract][Full Text] [Related]
8. Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes.
Imnadze M; Sjoberg DD; Vickers AJ
Eur Urol; 2016 Jan; 69(1):143-8. PubMed ID: 25913389
[TBL] [Abstract][Full Text] [Related]
9. Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance.
Hong SK; Sternberg IA; Keren Paz GE; Kim PH; Touijer KA; Scardino PT; Eastham JA
Eur Urol; 2014 Aug; 66(2):214-9. PubMed ID: 23954083
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
11. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
[TBL] [Abstract][Full Text] [Related]
12. Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.
Druskin SC; Mamawala M; Tosoian JJ; Epstein JI; Pavlovich CP; Carter HB; Trock BJ
J Urol; 2019 Jan; 201(1):98-104. PubMed ID: 30114397
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database.
McGinley KF; Sun X; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
Int J Urol; 2017 Aug; 24(8):611-617. PubMed ID: 28589550
[TBL] [Abstract][Full Text] [Related]
14. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology.
Kang JJ; Reiter RE; Steinberg ML; King CR
Eur Urol Oncol; 2018 Oct; 1(5):378-385. PubMed ID: 31158076
[TBL] [Abstract][Full Text] [Related]
15. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Grade Group 2 and 3 Prostate Cancer on Initial Versus Confirmatory Biopsy: Implications for Active Surveillance.
Perera M; Jibara G; Tin AL; Haywood S; Sjoberg DD; Benfante NE; Carlsson SV; Eastham JA; Laudone V; Touijer KA; Fine S; Scardino PT; Vickers AJ; Ehdaie B
Eur Urol Focus; 2023 Jul; 9(4):662-668. PubMed ID: 36566100
[TBL] [Abstract][Full Text] [Related]
17. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
18. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
19. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
[TBL] [Abstract][Full Text] [Related]
20. Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy.
Han JS; Toll AD; Amin A; Carter HB; Landis P; Lee S; Epstein JI
Urology; 2012 Oct; 80(4):883-8. PubMed ID: 22921697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
